Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
J Peripher Nerv Syst ; 28(2): 179-190, 2023 06.
Artículo en Inglés | MEDLINE | ID: mdl-36995049

RESUMEN

BACKGROUND AND AIMS: The expanding use of chemotherapy in curative cancer treatment has simultaneously resulted in a substantial and growing cohort of cancer survivors with prolonged disability from chemotherapy-induced peripheral neuropathy (CIPN). CIPN is associated with several commonly prescribed chemotherapeutics, including taxanes, platinum-based drugs, vinca alkaloids, bortezomib and thalidomide. These distinct classes of chemotherapeutics, with their varied neurotoxic mechanisms, often cause patients to suffer from a broad profile of neuropathic symptoms including chronic numbness, paraesthesia, loss of proprioception or vibration sensation and neuropathic pain. Decades of investigation by numerous research groups have provided substantial insights describing this disease. Despite these advances, there is currently no effective curative or preventative treatment option for CIPN and only the dual serotonin-norepinephrine reuptake inhibitor Duloxetine is recommended by clinical guidelines for the symptomatic treatment of painful CIPN. METHODS: In this review, we examine current preclinical models, with our analysis focused on translational relevance and value. RESULTS: Animal models have been pivotal in achieving a better understanding of the pathogenesis of CIPN. However, it has been challenging for researchers to develop appropriate preclinical models that are effective vehicles for the discovery of translatable treatment options. INTERPRETATION: Further development of preclinical models targeting translational relevance will promote value for preclinical outcomes in CIPN studies.


Asunto(s)
Antineoplásicos , Neoplasias , Neuralgia , Alcaloides de la Vinca , Animales , Antineoplásicos/toxicidad , Neoplasias/tratamiento farmacológico , Neuralgia/tratamiento farmacológico , Modelos Animales de Enfermedad
2.
Muscle Nerve ; 64(2): 225-234, 2021 08.
Artículo en Inglés | MEDLINE | ID: mdl-34036599

RESUMEN

INTRODUCTION/AIMS: Clinically, the chemotherapeutic agent oxaliplatin can cause peripheral neuropathy, impaired balance, and muscle wastage. Using a preclinical model, we investigated whether exercise intervention could improve these adverse conditions. METHODS: Mice were chronically treated with oxaliplatin alone or in conjunction with exercise. Behavioral studies, including mechanical allodynia, rotarod, open-field, and grip-strength tests, were performed. After euthanasia, multiple organs and four different muscle types were dissected and weighed. The cross-sectional area (CSA) of muscle fibers in the gastrocnemius muscle was assessed and gene expression analysis performed on the forelimb triceps muscle. RESULTS: Oxaliplatin-treated mice displayed reduced weight gain, mechanical allodynia, and exploratory behavior deficits that were not significantly improved by exercise. Oxaliplatin-treated exercised mice showed modest evidence of reduced muscle wastage compared with mice treated with oxaliplatin alone, and exercised mice demonstrated evidence of a mild increase in CSA of muscle fibers. DISCUSSION: Exercise intervention did not improve signs of peripheral neuropathy but moderately reduced the negative impact of oxaliplatin chemotherapy related to muscle morphology, suggesting the potential for exploring the impact of exercise on reducing oxaliplatin-induced neuromuscular toxicity in cancer patients.


Asunto(s)
Hiperalgesia/terapia , Enfermedades del Sistema Nervioso Periférico/terapia , Condicionamiento Físico Animal/fisiología , Animales , Antineoplásicos/farmacología , Modelos Animales de Enfermedad , Hiperalgesia/inducido químicamente , Masculino , Ratones Endogámicos C57BL , Oxaliplatino/farmacología , Umbral del Dolor/efectos de los fármacos , Enfermedades del Sistema Nervioso Periférico/inducido químicamente
3.
Brain Struct Funct ; 228(5): 1177-1189, 2023 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-37160458

RESUMEN

Although the silver fox (Vulpes vulpes) has been largely overlooked by neuroscientists, it has the potential to serve as a powerful model for the investigation of brain-behavior relationships. The silver fox is a melanistic variant of the red fox. Within this species, the long-running Russian farm-fox experiment has resulted in different strains bred to show divergent behavior. Strains bred for tameness, aggression, or without selection on behavior present an excellent opportunity to investigate neuroanatomical changes underlying behavioral characteristics. Here, we present a histological and MRI neuroanatomical reference of a fox from the conventional strain, which is bred without behavioral selection. This can provide an anatomical basis for future studies of the brains of foxes from this particular experiment, as well as contribute to an understanding of fox brains in general. In addition, this can serve as a resource for comparative neuroscience and investigations into neuroanatomical variation among the family Canidae, the order Carnivora, and mammals more broadly.


Asunto(s)
Agresión , Zorros , Animales , Encéfalo
4.
Eur J Cancer ; 73: 22-29, 2017 03.
Artículo en Inglés | MEDLINE | ID: mdl-28104535

RESUMEN

Chemotherapy-induced peripheral neuropathy (CIPN) and associated neuropathic pain are challenging complications of cancer treatment. Many of the major classes of chemotherapeutics can cause neurotoxicity and significantly modulate the immune system. There is ongoing investigation regarding whether reciprocal crosstalk between the nervous and immune systems occurs and, indeed, contributes to neuropathic pain during treatment with chemotherapeutics. An emerging concept is that neuroinflammation is one of the major mechanisms underlying CIPN. Here, we discuss recent findings, which provide insight into this complex process of neuroimmune interactions. Findings show limited infiltration of leukocytes into the nervous system of CIPN animals and varying degrees of peripheral and central glial activation depending on the chemotherapeutic drug, dose, schedule, and timing. Most evidence suggests an increase in pro-inflammatory cytokine expression and changes in immune signalling pathways. There is, however, limited evidence available from human studies and it remains unclear whether neuroinflammatory responses are the cause of neuropathy or a bystander effect of the chemotherapy treatment.


Asunto(s)
Inmunidad Adaptativa/efectos de los fármacos , Antineoplásicos/efectos adversos , Inmunidad Innata/efectos de los fármacos , Neuralgia/inducido químicamente , Enfermedades del Sistema Nervioso Periférico/inducido químicamente , Animales , Quimiocinas/metabolismo , Citocinas/metabolismo , Humanos , Neuralgia/inmunología , Neuroglía/efectos de los fármacos , Síndromes de Neurotoxicidad/etiología , Enfermedades del Sistema Nervioso Periférico/inmunología , Transducción de Señal/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA